Search results
Results from the WOW.Com Content Network
In childhood, T-cell acute lymphoblastic leukemia (T-ALL) patients can expect a 5-year event-free survival (EFS) rate of 70% and an overall survival (OS) rate of 80%. [1] Among the approximately 25% of children who relapse, survival rates drop to 30-50%, with patients generally showing a much poorer prognosis. [ 1 ]
The Organization (2016) also termed a third type of intestinal T cell lymphoma that could not be classified as ATL or MEITL as intestinal T cell lymphoma, not otherwise specified. [6] MEITL is a highly aggressive GI tract lymphoma [7] which typically has had very short survival times following its diagnosis. [2]
The five-year survival rate in the United States for all Hodgkin lymphoma subtypes is 85%, [4] while that for non-Hodgkin lymphomas is 69%. [15] Worldwide, lymphomas developed in 566,000 people in 2012 and caused 305,000 deaths. [16] They make up 3–4% of all cancers, making them as a group the seventh-most-common form.
T-cell lymphoma is a rare form of cancerous lymphoma affecting T-cells. [1] Lymphoma arises mainly from the uncontrolled proliferation of lymphocytes, such as T-cells, and can become cancerous. [2] T-cell lymphoma is categorized under Non-Hodgkin lymphoma (NHL) and represents less than 15% of all Non-Hodgkin's diseases in the category. [3]
The evidence is very uncertain about the effect of Nivolumab for patients with a Hodgkin's lymphoma e.g. on the overall survival. [50] Increased age is an adverse risk factor for Hodgkin lymphoma, but in general elderly people (≥ 60 years of age) without major comorbidities are sufficiently fit to tolerate therapy with curative intent.
A phase 1 study sponsored by the NIH and Mayo Clinic USA is recruiting patients with peripheral T-cell lymphomas, including EATL, to study the efficacy and toxicity of nivolumab. Nivolumab is monoclonal antibody checkpoint inhibitor that binds to the programmed cell death protein 1 (PD-1) thereby blocking this protein from being activated by ...
The 14 year survival rates for patients with Lennert lymphoma, 56%, was significantly (p-value=003, Logrank test) greater than the 10% survival rate for patients with other types of peripheral T-cell lymphomas
Burkitt's lymphoma is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal center.It is named after Denis Parsons Burkitt, the Irish surgeon who first described the disease in 1958 while working in equatorial Africa.